Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-08-29
2006-08-29
Kemmerer, Elizabeth (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C530S350000, C530S351000, C530S387100, C530S388220, C436S501000, C514S002600, C435S007210
Reexamination Certificate
active
07097838
ABSTRACT:
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
REFERENCES:
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6323329 (2001-11-01), Bullerdiek
patent: 6448223 (2002-09-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 2002/0009749 (2002-01-01), Ozaki et al.
patent: 2003/0113323 (2003-06-01), Tracey et al.
patent: 2003/0143194 (2003-07-01), Tracey et al.
patent: 1 079 849 (2002-01-01), None
patent: 362166897 (1986-01-01), None
patent: WO 96/25493 (1996-08-01), None
patent: WO 97/23611 (1997-07-01), None
patent: WO 99/59609 (1999-11-01), None
patent: WO 02/074337 (2002-09-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 2004/004763 (2004-01-01), None
Rauvala, H. et al., Journal of Cell Biology 107(2294-2305)1988.
Benjamini-E. Immunology, A Short Course, 1991, p. 40.
Abraham, E., et al., “Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation,”J. Immunol., 165:2950-2954 (2000).
Andersson, U., et al., “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes,”J. Exp. Med., 192:565-570 (2000).
Bustin, M. “Revised Nomenclature for High Mobility Group (HMG) Chromosomal Proteins,”Trends Biochem. Sci., 26:152-153 (2001).
Degryse, B., et al., “The High Mobility Group (HMG) Boxes of the Nuclear Protein HMG1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells,”J. Cell Biol., 152:1197-1206 (2001).
Wang, H., et al., “Proinflammatory Cytokines (Tumor Necrosis Factor and Interleukin 1) Stimulate Release of High Mobility Group Protein-1 by Pituicytes,”Surgery, 126:389-392(1999).
Falciola, L., et al., “High Mobility Group 1 Protein is Not Stably Associated with the Chromosomes of Somatic Cells,”J. Cell Biol., 137 (1) :19-26 (1997).
Vanderbilt, J.N., et al., “Monoclonal Antibodies as Probes for the Complexity, Phylogeny, and Chromatin Distribution of High Mobility Group Chromosomal Proteins 1 and 2,”J. Biol. Chem., 260(16) :9336-9345 (1985).
Bustin, M., et al., “Antigenic Determinants of High Mobility Group Chromosomal Proteins 1 and 2,”Biochem., 21:6773-6777 (1982).
Tsuneoka, M., et al., “Monoclonal Antibody Against Non-Histone Chromosomal Protein High Mobility Group 1 Co-Migrates With High Mobility Group 1 Into the Nucleus,”J. Biol. Chem., 261(4) :1829-1834 (1986).
Bianchi, M.E., et al., “The DNA Binding Site of HMG1 Protein is Composed of Two Similar Segments (HMG Boxes) , Both of Which Have Counterparts in Other Eukaryotic Regulatory Proteins,”EMBO J.11(3) :1055-1063 (1992).
Bustin, M., et al., “Immunological Relatedness of High Mobility Group Chromosomal Proteins from Calf Thymus,”J. Biol. Chem., 253(5):1694-1699 (1978).
Rauvala, H. and Pihlaskari, R., “Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons,”J. Biol. Chem., 262(34):16625-16635 (1987).
Daston, M. M. and Ratner, N., “Expression of P30, a Protein with Adhesive Properties, in Schwann Cells and Neurons of the Developing and Regenerating Peripheral Nerve,”J. Cell Biol., 112(6):1229-1239 (1991).
Parkinnen, J., et al. “Amphoterin, the 30-kDa Protein in a Family of HMG1-type Polypeptides,”J. Biol. Chem., 268(26):19726-19738 (1993).
Sobajima, J., et al. “High Mobility Group (HMG) Non-histone Chromosomal Proteins HMG1 and HMG2 are Significant Target Antigens of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Autoimmune Hepatitis,”Gut, 44:867-873 (1999).
Ma, W., et al. “Detection of Anti-Neutrophil Cytoplasmic Antibodies in MRL/Mp-Ipr/Ipr Mice and Analysis of Their Target Antigen,”Autoimmunity, 32(4):281-291 (2000).
Banks, G. C., et al., “The HMG-I(Y) A T-hook Peptide Motif Confers DNA-binding Specificity to a Structured Chimeric Protein,”J. Biol. Chem., 274(23):16536-16544 (1999).
Scaffidi, P., et al., “Release of chromatin protein HMGB1 by Necrotic Cells Triggers Inflammation,”Nature, 418:191-95 (2002).
Abaza, M.-S. I. and Atassi, M. Z., “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin,”J. Protein Chem.11(5):433-444 (1992).
Colman, P. M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,”Res. Immunol., 145(1):33-36 (1994).
Freeman, B. D., et al., “The Role of Inflammation in Sepsis and Septic Shock: A Meta-Analysis of Both Clinical and Preclinical Trials of Anti-Inflammatory Therapies,” inInflammation: Basic Principals and Clinical Correlates(John I. Gallin and Ralph Snyderman eds., Lippincott, Williams & Wilkins, Philadelphia, 3rded. 1999), pp. 965-975.
Lederman, S., et al., “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody OKT,”Mol. Immunol., 28(11):1171-1181 (1991).
Czura, C., et al., “Dual Roles for HMGB1: DNA Binding and Cytokine,”J. Endotoxin Res., 7(4):315-321 (2001).
Wen, L., et al., “A Human Placental cDNA Clone that Encodes Nonhistone Chromosomal Protein HMG-1,”Nucleic Acids Res., 17(3):1197-1213 (1989).
Uesugi, H., et al., “Prevalence and Characterization of Novel pANCA, Antibodies to the High Mobility Group Non-Histone Chromosomal Proteins HMG1 and HMG2, in Systemic Rheumatic Diseases,”J. Rheumatol., 25(4):703-709 (1998).
Passalacqua, M., et al., “Stimulated Astrocytes Release High-Mobility Group 1 Protein, an Inducer of Lan-5 Neuroblastoma Cell Differentiation,”Neuroscience, 82(4):1021-1028 (1998).
Chou, D. K. H., et al., “Identity of Nuclear High-Mobility-Group Protein, HMG-1, and Sulfoglucuronyl Carbohydrate-Binding Protein, SBP-1, in Brain,”J. Neurochem., 77:120-131 (2001).
Imamura, T., et al., “Interaction with p53 Enhances Binding of Cisplatin-Modified DNA by High Mobility Group 1 Protein,”J. Biol. Chem., 276(10):7534-7540 (2001).
Ise, T., et al., “Transcription Factor Y-Box Binding Protein 1 Binds Preferentially to Cisplatin-Modified DNA and Interacts With Proliferating Cell Nuclear Antigen,”Cancer Res., 59:342-346 (1999).
Jung, F., et al., “Antibodies Against a Peptide Sequence Located in the Linker Region of the HMG-1/2 Box Domains in Sera From Patients With Juvenile Rheumatoid Arthritis,”Arthritis Rheum., 40(10):1803-1809 (1997).
Bianchi, M. E., et al., “Specific Recognition of Cruciform DNA by Nuclear Protein HMG1,”Science, 243:1056-1059 (1989).
Suda, T., et al., “A Novel Activity of HMG Domains: Promotion of the Triple-Stranded Complex Formation Between DNA Containing (GGA/TCC)IIand d(GGA)IIOligonucleotides,”Nucleic Acids Res., 24(23):4733-4740 (1996).
Ayer, L. M., et al., “Antibodies to HMG Proteins in Patients With Drug-Induced Autoimmunity,”Arthritis Rheum., 37(1):98-103 (1994).
Rauvala, H., et al., “The Adhesive and Neurite-Promoting Molecule p30: Analysis of the Amino-Terminal Sequence and Production of Antipeptide Antibodies That Detect p30 at the Surface of Neuroblastoma Cells and of Brain Neurons,”J. Cell
Tracey Kevin J.
Wang Haichao
Brannock Michael
Hamilton Brook Smith & Reynolds P.C.
Kemmerer Elizabeth
The Feinstein Institute for Medical Research
LandOfFree
Antagonists of HMG1 for treating inflammatory conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of HMG1 for treating inflammatory conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of HMG1 for treating inflammatory conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3651725